3 news items
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
COGT
23 May 24
Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential commercial launch of bezuclastinib for patients
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
COGT
23 May 24
of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the long-term safety and tolerability profile
Cogent Biosciences Reports First Quarter 2024 Financial Results
COGT
7 May 24
Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the Company's clinical development plans and timelines
- Prev
- 1
- Next